Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6411 posts found.

Whistleblower accuses Novartis of paying bribes in Turkey to push sales

April 1, 2016 Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters

An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …
News
janssen_latest_logo_on_sign_closer

Janssen to stop fulranumab development in osteoarthritis pain

April 1, 2016 Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …
News
pfizerbrussels

Fake press release on drug pricing “erroneously attributed” to Pfizer

April 1, 2016 Medical Communications Pfizer, fake, false, legal action, press release, washington post

Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
News
fda

FDA releases biosimilars labelling guidance

April 1, 2016 Manufacturing and Production, Medical Communications, Research and Development FDA, biosimilars

The US Food and Drug Administration (FDA) has issued draft guidance on the labelling of biosimilar drugs. The guidance states …
News

Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment

April 1, 2016 Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
News
samsung_bioepis

Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

March 31, 2016 Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
News
valeant

Valeant’s outgoing CEO subpoenaed by US congressional committee

March 29, 2016 Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed

The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
News
msd

MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016 Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
News
novartis_pic

Novartis settles bribery charges in China for $25m

March 24, 2016 Medical Communications, Sales and Marketing Novartis

Novartis will pay $25 million to the US Government’s Securities and Exchange Commission to settle charges that it bribed healthcare …
News
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016 Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
News
fda_sign_web

FDA announces strongest warnings for opioid pain medications

March 23, 2016 Medical Communications, Research and Development FDA, abuse, addiction, boxed, label, misuse, opioids, public health, restrictions, safety, warnings

The US Food and Drug Administration has announced class-wide safety labelling changes for immediate release (IR) opioid pain medications. The …
News
fda_building

FDA bans clinical trial co-ordinator who faked patient samples and stole funds

March 22, 2016 Manufacturing and Production, Medical Communications FDA, HIV, clinical trials, faked, forgery, mcquerry, prison

The US Food and Drug Administration has permanently banned a clinical trial co-ordinator who was found to have falsified patient …
News
christa_wirthumer-hoche

European Medicines Agency elects Christa Wirthumer-Hoche as new chair of management board

March 21, 2016 Medical Communications, Research and Development Christa Wirthumer-Hoche, EMA, European Medicines Agency, chair, chairperson, wirthumer-hoche

Christa Wirthumer-Hoche has been elected chair of the management board of the European Medicine’s Agency. She has served as vice …
Appointment
janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016 Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016 Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
News
The Gateway to Local Adoption Series

Latest content

Closing the immunisation gap: partnership working that delivered at scale

June 5, 2026

Phase 2 study explores imaging approach for interstitial lung disease

June 5, 2026

Laverock secures funding for gene-control platform development

June 4, 2026

LifeArc and Elpida partner to advance gene therapies for ultra-rare childhood diseases

June 3, 2026

Well Pharmacy and Alzheimer’s Society launch dementia partnership

June 2, 2026